```html

Koch Disease (Tuberculosis) – Comprehensive Medical Guide

Overview

Koch disease, more commonly known as tuberculosis (TB), is an infectious disease caused by the bacterium Mycobacterium tuberculosis. It primarily affects the lungs (pulmonary TB) but can involve virtually any organ (extrapulmonary TB). TB is transmitted through airborne droplets when a person with active pulmonary disease coughs, sneezes, speaks, or sings.

Globally, TB remains one of the top 10 causes of death and the leading cause of death from a single infectious agent, surpassing HIV/AIDS. In 2022 the World Health Organization (WHO) estimated 10.6 million new cases and **1.6 million deaths** worldwide.<sup>[1]</sup> In the United States, the Centers for Disease Control and Prevention (CDC) reported **8,200 cases** in 2023, a modest increase after years of decline.<sup>[2]</sup>

Anyone can become infected, but certain groups are at higher risk: people living with HIV, close contacts of active TB cases, individuals with diabetes, those on immunosuppressive therapy, and people living in crowded or poorly ventilated settings.

Symptoms

TB symptoms vary according to whether the infection is latent (the bacteria are present but inactive) or active. Only active TB produces symptoms and can be transmitted.

Pulmonary (Lung) TB

• Persistent cough lasting ≥ 2 weeks – may be dry or produce sputum.
• Hemoptysis – coughing up blood or blood‑streaked sputum.
• Chest pain – often pleuritic (sharp pain that worsens with deep breathing).
• Fever – low‑grade, often in the evenings.
• Night sweats – drenching sweats that soak sleepwear.
• Unexplained weight loss – “wasting” despite normal intake.
• Fatigue and weakness – generalized lack of energy.
• Loss of appetite.

Extrapulmonary TB

• Lymph node TB – painless swelling, often in the neck or supraclavicular area.
• TB meningitis – severe headache, neck stiffness, altered mental status, especially in children.
• Spinal (Pott) disease – chronic back pain, spinal rigidity, possible neurologic deficits.
• Genitourinary TB – frequency, dysuria, hematuria, infertility.
• TB pericarditis – chest discomfort, shortness of breath, signs of heart failure.
• Disseminated (miliary) TB – fever, weight loss, organ‑specific symptoms; radiographs show “millet‑seed” nodules.

Because symptoms develop slowly (weeks to months), many patients attribute them to less serious illnesses, delaying diagnosis.

Causes and Risk Factors

Primary Cause

TB is caused by infection with Mycobacterium tuberculosis. The organism is a slow‑growing, aerobic, acid‑fast bacillus that can survive within macrophages by inhibiting phagosome‑lysosome fusion.

Transmission

• Inhalation of droplets containing 1‑10 viable bacilli from a person with *untreated* or *poorly treated* pulmonary TB.
• Rarely, ingestion of contaminated milk (historically M. bovis), or direct inoculation into the skin (e.g., needlestick injuries).

Risk Factors

• Immunosuppression: HIV infection (TB risk 20‑30 × higher), organ transplantation, chemotherapy, corticosteroids, biologics (TNF‑α inhibitors).
• Chronic diseases: Diabetes mellitus triples the risk; chronic kidney disease, silicosis, and severe malnutrition also increase susceptibility.
• Living conditions: Overcrowded housing, prisons, shelters, refugee camps, and long‑term care facilities.
• Substance use: Tobacco smoking, alcohol misuse, illicit drug use (especially injection).
• Age: Children < 5 years and the elderly have higher rates of progression from latent to active disease.
• Recent infection: Close contact with an infectious case within the past 2 years.

Diagnosis

Accurate diagnosis requires a combination of clinical assessment, microbiologic testing, and imaging.

Step‑wise Approach

1. Medical History & Physical Exam: Identify risk factors, symptom duration, and exposure.
2. Chest Radiography: Preferred first‑line imaging. Typical findings include infiltrates in the upper lobes, cavitary lesions, or hilar lymphadenopathy.
3. Sputum Microscopy (Ziehl‑Neelsen stain): Detects acid‑fast bacilli (AFB) within 1–2 hours. Sensitivity ≈ 50‑60 % but specificity is high.
4. Nucleic Acid Amplification Tests (NAAT): e.g., GeneXpert MTB/RIF. Provides rapid detection of *M. tuberculosis* and rifampin resistance within 2 hours. Sensitivity > 90 % in smear‑positive specimens.
5. Culture: Gold standard; solid (Lowenstein‑Jensen) or liquid (MGIT) media. Takes 2–8 weeks but allows drug‑susceptibility testing (DST).
6. Interferon‑Gamma Release Assays (IGRAs) or Tuberculin Skin Test (TST): Identify latent TB infection (LTBI). IGRAs (e.g., QuantiFERON‑TB Gold) are preferred in BCG‑vaccinated populations.
7. Additional Imaging: CT scan for complex pulmonary disease; MRI for TB meningitis or spinal involvement.
8. Extrapulmonary Specimens: Biopsy, cerebrospinal fluid (CSF) analysis, urine culture, or pleural fluid analysis, depending on the organ involved.

Special Considerations

In children and people living with HIV, sputum may be difficult to obtain; gastric aspirates or induced sputum are alternative specimens. For suspected drug‑resistant TB, rapid molecular tests for mutations in *rpoB* (rifampin) and *katG*/*inhA* (isoniazid) are essential.

Treatment Options

Treatment aims to eradicate the bacteria, prevent relapse, and limit transmission. Regimens differ for drug‑susceptible, drug‑resistant, and latent infection.

1. Drug‑Susceptible Pulmonary TB

Standard 6‑month regimen (per WHO and CDC guidelines):

• Intensive phase (2 months): Isoniazid (INH) + Rifampin (RIF) + Pyrazinamide (PZA) + Ethambutol (EMB).
• Continuation phase (4 months): Isoniazid + Rifampin.

All drugs are taken daily (or three times weekly under directly observed therapy—DOT), with dosing adjusted for weight and renal/hepatic function.

2. Latent TB Infection (LTBI)

Goal: Prevent progression to active disease.

• Isoniazid 300 mg daily for 9 months (preferred).
• Rifampin daily for 4 months (alternative).
• Isoniazid + Rifapentine once weekly for 12 weeks (3HP regimen) – high completion rates.

3. Drug‑Resistant TB (MDR‑TB, XDR‑TB)

MDR‑TB = resistance to at least INH and RIF. XDR‑TB = MDR‑TB plus resistance to a fluoroquinolone and at least one second‑line injectable.

• Longer regimens (12‑20 months) using second‑line agents: fluoroquinolones (e.g., levofloxacin, moxifloxacin), injectable agents (amikacin, capreomycin), bedaquiline, linezolid, cycloserine, and pretomanid.
• All-oral regimens (bedaquiline + linezolid + fluoroquinolone) are now preferred, reducing toxicity associated with injectables.
• Therapeutic drug monitoring and close adverse‑event surveillance are essential.

4. Adjunctive Therapies

• Corticosteroids: Recommended for TB meningitis and pericardial TB to reduce inflammation.
• Surgical intervention: Indicated for massive hemoptysis, localized cavitary disease not responding to medication, or spinal compression.
• Nutrition support: High‑calorie, protein‑rich diet to counteract cachexia.

5. Lifestyle & Supportive Measures

• Adherence counseling and DOT (in‑person or video‑observed).
• Alcohol cessation, smoking cessation, and management of comorbidities (e.g., diabetes).
• Infection control: proper ventilation, wearing a surgical mask until sputum conversion.

Living with Koch Disease (Tuberculosis)

Successful treatment and quality of life depend on both medical therapy and daily self‑care.

Medication Adherence

• Set a fixed daily time; use pillboxes or smartphone reminders.
• Report side effects promptly; many are reversible (e.g., mild hepatitis from INH).
• Never stop medication without consulting your provider, even if you feel better.

Nutrition & Hydration

• Consume 2,100–2,500 kcal/day for adults; add protein‑rich foods (lean meat, beans, dairy).
• Stay hydrated; adequate fluids help with medication metabolism and mucus clearance.

Physical Activity

• Gentle aerobic activity (walking, cycling) 20‑30 minutes most days improves lung function and combats fatigue.
• Avoid high‑intensity exercise during fever spikes.

Infection Control at Home

• Keep windows open or use exhaust fans to increase air exchange.
• Sleep in a separate bedroom if possible until sputum tests are negative (usually 2 weeks of therapy).
• Cover mouth/nose with a tissue or mask when coughing; dispose of tissues safely.
• Regularly clean surfaces with a bleach solution (1 part bleach to 9 parts water).

Psychosocial Support

• TB can be stigmatizing; seek counseling, join support groups, or connect with local public‑health outreach.
• Financial assistance programs (e.g., CDC’s TB Elimination Program) may help cover medication and travel costs.

Prevention

Primary Prevention

• Vaccination: Bacille Calmette‑Guérin (BCG) vaccine offers variable protection against severe pediatric TB (meningeal and miliary forms) but limited efficacy against pulmonary TB in adults. Recommended in high‑burden countries.
• Infection‑Control Practices: Adequate ventilation, UV germicidal irradiation in high‑risk settings, and respiratory hygiene.

Secondary Prevention (Latent Infection Treatment)

• Screen high‑risk groups (close contacts, HIV‑positive individuals, healthcare workers) with IGRA or TST.
• Treat LTBI with recommended regimens (see Treatment Options) to curb progression.

Community‑Level Measures

• Active case finding and contact tracing by public health authorities.
• Directly observed therapy (DOT) programs to ensure completion.
• Public education campaigns to reduce stigma and promote early evaluation of cough lasting > 2 weeks.

Complications

If TB is left untreated or inadequately treated, the bacteria can cause irreversible damage.

• Pulmonary complications: Cavitation, bronchiectasis, hemoptysis, and fibrosis leading to chronic respiratory insufficiency.
• TB meningitis: Hydrocephalus, seizures, permanent neurologic deficits, or death.
• Spinal (Pott) disease: Vertebral collapse, spinal cord compression, paralysis.
• Disseminated (miliary) TB: Multi‑organ failure, especially in immunocompromised hosts.
• Drug‑induced toxicities: Hepatotoxicity (INH, RIF, PZA), optic neuritis (EMB), peripheral neuropathy (INH), and QT prolongation (fluoroquinolones, bedaquiline).

When to Seek Emergency Care

References

1. World Health Organization. Global Tuberculosis Report 2023. Geneva: WHO; 2023. Link.
2. Centers for Disease Control and Prevention. 2023 Tuberculosis Surveillance Report. Atlanta, GA: CDC; 2024. Link.
3. Mayo Clinic. Tuberculosis (TB) – Symptoms and causes. Link.
4. Cleveland Clinic. Tuberculosis: Diagnosis and treatment. Link.
5. National Institute of Allergy and Infectious Diseases. Tuberculosis Treatment Guidelines. Link.

```